Can't Afford Weight Loss Medication? Every Low-Cost GLP-1 Option in 2026
A complete guide to every legitimate low-cost GLP-1 option in 2026 — from $99/month compounded semaglutide to patient assistance programs, 340B clinics, and insurance strategies. No option left out.
Written by Trimi Medical Team. Medically reviewed by Trimi Medical Review Board. This article is for informational purposes and does not replace personalized medical advice.
More on Cost & Access
GLP-1 weight loss medications — semaglutide and tirzepatide — are among the most effective treatments for obesity ever developed. They are also among the most expensive. At $900–$1,500/month for brand-name medications, they are priced out of reach for most Americans who do not have insurance coverage.
But cost alone should not decide whether you can access effective treatment. This guide covers every legitimate low-cost GLP-1 option available in 2026 — organized by speed, income requirements, and practical accessibility — so you can find the path that fits your situation.
Quick Reference: Every Low-Cost GLP-1 Option
| Option | Estimated monthly cost | Income requirement | Time to first dose |
|---|---|---|---|
| Compounded semaglutide (Trimi) | $99/month | None | 5–10 business days |
| Compounded tirzepatide (Trimi) | $125/month | None | 5–10 business days |
| NovoCare patient assistance (Wegovy/Ozempic) | Free (if eligible) | Yes — income-based | 3–6 weeks |
| LillyHelp patient assistance (Zepbound/Mounjaro) | Free (if eligible) | Yes — income-based | 3–6 weeks |
| 340B community health center | Varies — often $0–$50 | Some programs require low income | Varies — depends on facility |
| Insurance with approved prior auth | $0–$150 copay | None (need coverage) | 4–12 weeks (PA process) |
| Copay savings card (insured patients only) | $0–$25/month | No (requires commercial insurance) | Same as insurance PA |
Option 1: Compounded Semaglutide — $99/Month, No Income Requirements
For most patients who cannot afford brand-name GLP-1 medications, compounded semaglutide from a licensed telehealth provider is the most practical starting point. It is available to any clinically eligible patient, requires no income documentation, and can be started within days.
What is compounded semaglutide?
Compounded semaglutide is the same active molecule as brand-name Wegovy and Ozempic — semaglutide, a GLP-1 receptor agonist — prepared by licensed compounding pharmacies using pharmaceutical-grade active pharmaceutical ingredient (API). The clinical mechanism and expected weight-loss outcomes are identical. The price difference exists because compounding pharmacies do not carry Novo Nordisk's patent premium, marketing costs, or commercial manufacturing overhead.
How Trimi delivers compounded semaglutide at $99/month
- Online health assessment reviewed by a board-certified provider within 24 hours
- Prescription sent to an FDA-registered, PCAB-accredited compounding pharmacy
- Third-party potency, sterility, and endotoxin testing on every batch
- Delivery to your door in 5–7 business days including injection supplies and dose schedule
- Monthly refills at $99/month with ongoing provider access
More detail: is $99 semaglutide real?
Option 2: Manufacturer Patient Assistance Programs
Both major GLP-1 manufacturers offer patient assistance programs for patients who qualify by income and insurance status.
Novo Nordisk NovoCare (Ozempic & Wegovy)
NovoCare provides free or reduced-cost Ozempic and Wegovy to patients who are uninsured, have insurance that does not cover the medication, and meet income eligibility criteria. Income limits are typically set below 400% of the federal poverty level, but check NovoCare's current terms directly as they are updated periodically.
- Application requires: proof of income, insurance status, prescription from a provider
- Approval time: typically 3–6 weeks
- Benefit: brand-name medication at no or reduced cost
Eli Lilly LillyHelp (Mounjaro & Zepbound)
LillyHelp provides free Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for weight loss) to patients who meet income and insurance eligibility criteria. Similar structure to NovoCare — income-based, requires an application, and provides brand-name medication.
- Application requires: income documentation, insurance status, provider prescription
- Approval time: typically 3–6 weeks
- Benefit: brand-name tirzepatide at no or reduced cost
Important: Patient assistance programs are valuable but have real limitations — income thresholds, documentation requirements, and 3–6 week timelines. Many patients use compounded semaglutide while their patient assistance application is being processed to avoid treatment delays.
Option 3: 340B Program at Community Health Centers
The 340B Drug Pricing Program is a federal program that requires pharmaceutical manufacturers to provide covered outpatient drugs to qualifying healthcare organizations at dramatically reduced prices. Federally Qualified Health Centers (FQHCs), safety-net hospitals, and other qualifying facilities can access medications at 25–50% or more below wholesale acquisition cost — and many pass those savings to patients.
If you are uninsured or have a low income, receiving your obesity care at a 340B-eligible FQHC may be the lowest-cost brand-name option available to you. FQHCs also use a sliding-scale fee structure for clinical visits.
- Find your local FQHC at findahealthcenter.hrsa.gov
- Call ahead and ask specifically about GLP-1 medications and 340B pricing
- Not all 340B facilities stock GLP-1 drugs — availability varies by location
- Clinical visit may require sliding-scale fee based on income
Option 4: Insurance Coverage — What to Know in 2026
If you have commercial insurance, the first step is to verify your plan's current formulary for GLP-1 medications. Coverage has expanded significantly since 2022 but remains inconsistent across plans.
Commercial insurance
Coverage rates for GLP-1 weight-loss medications on commercial plans increased substantially between 2023 and 2026 as employers responded to employee demand and growing clinical evidence. However, prior authorization is almost universal, and denial rates on first submission remain high. See our full guide on what to do when prior authorization is denied.
Medicare
Medicare Part D coverage of GLP-1 medications for weight loss has expanded under recent policy changes, but coverage is not universal across all Part D plans. Medicare currently covers semaglutide under certain cardiovascular and diabetes indications. Contact your specific Part D plan to verify current formulary status for Wegovy and any applicable prior authorization requirements.
Medicaid
Medicaid coverage varies enormously by state. Some states have added GLP-1 medications to Medicaid formularies with specific PA criteria; others exclude anti-obesity drugs entirely. Check your state Medicaid program's preferred drug list directly.
Option 5: Manufacturer Copay Cards (Commercially Insured Patients)
If you have commercial insurance that covers Ozempic, Wegovy, Mounjaro, or Zepbound — but your copay is still high — manufacturer copay cards can reduce your monthly cost to as low as $0–$25.
- Novo Nordisk Wegovy savings card: reduces copay to as low as $0 for eligible commercially insured patients
- Novo Nordisk Ozempic savings card: reduces copay to as low as $25/month for eligible patients
- Eli Lilly Zepbound savings card: similar structure for tirzepatide
- These cards do NOT work for Medicare or Medicaid patients — federal anti-kickback law prohibits it
- Copay cards are only active on an approved, covered prescription — they do not help if coverage is denied
Choosing the Right Path: A Decision Framework
If you need to start treatment within 1–2 weeks:
Compounded semaglutide at $99/month through Trimi is the only option that consistently delivers within that window. All other paths involve 3–12 weeks of processing time.
If you have a very low income and can wait 4–6 weeks:
Apply for NovoCare (Ozempic/Wegovy) or LillyHelp (Mounjaro/Zepbound) patient assistance. If eligible, brand-name medication is free. Start compounded semaglutide in the meantime while the application processes.
If you have commercial insurance but your PA was denied:
File an appeal and start compounded semaglutide simultaneously. If the appeal succeeds, transition to insurance coverage. If not, $99/month compounded is your ongoing solution.
If you are on Medicare:
Verify current Part D formulary with your specific plan. If not covered, NovoCare may apply. Compounded semaglutide is available as a cash-pay alternative with no Medicare billing.
If you are on Medicaid:
Check your state's PDL. If GLP-1 drugs are not covered, patient assistance programs and compounded semaglutide are the alternatives. Compounding pharmacy programs typically do not bill Medicaid.
What About Tirzepatide? The GIP/GLP-1 Alternative
Tirzepatide (brand-name Mounjaro for diabetes, Zepbound for weight loss) is a dual GIP/GLP-1 receptor agonist that produces even greater average weight loss than semaglutide in head-to-head comparisons. SURMOUNT-1 data showed average weight loss of 20.9% at the highest dose over 72 weeks.
Brand-name Zepbound retails for $1,000–$1,400/month. Compounded tirzepatide is available through Trimi at $125/month using the same structure — online evaluation, accredited pharmacy, same-day provider access.
For patients who are not responding to semaglutide or want the additional GIP mechanism from the start, compounded tirzepatide at $125/month is a significant upgrade at a modest cost difference from compounded semaglutide.
The Cost of Not Treating Obesity
A consideration that often gets lost in affordability discussions: the downstream costs of undertreated obesity are substantial. Type 2 diabetes, cardiovascular disease, sleep apnea, joint disease, and obesity-related cancers each carry their own treatment costs that can dwarf the monthly cost of GLP-1 medication. At $99/month, even one year of compounded semaglutide costs less than a single hospital visit for a preventable obesity complication.
This is not an argument to pressure anyone into treatment they cannot afford — it is a context for understanding that even the $99/month compounded option represents a meaningful investment with a plausible return on health outcomes.
Frequently Asked Questions
What is the cheapest GLP-1 medication available in 2026?
Compounded semaglutide through a licensed telehealth provider like Trimi is the least expensive GLP-1 option available without income requirements, starting at $99/month. For patients who qualify by income, manufacturer patient assistance programs may provide brand-name semaglutide at no cost. For insured patients with coverage, copay cards can reduce costs to $0–$25/month.
Are there free GLP-1 medications for people who truly cannot afford them?
Yes, through manufacturer patient assistance programs. Novo Nordisk's NovoCare program and Eli Lilly's LillyHelp provide free brand-name GLP-1 medications to uninsured or underinsured patients who meet income criteria (typically below 400% of the federal poverty level). These require income documentation and approval timelines of several weeks.
Can I get semaglutide at a community health center?
Potentially yes. Federally Qualified Health Centers (FQHCs) and other 340B-eligible safety-net clinics can purchase medications at dramatically reduced prices and may pass those savings to patients. If you are uninsured or have a low income, receiving care at an FQHC is worth exploring. Call local FQHCs in your area and ask specifically about GLP-1 availability and pricing.
Is compounded semaglutide at $99/month actually the same drug as Wegovy?
The active ingredient is identical — semaglutide, a GLP-1 receptor agonist. Wegovy is manufactured by Novo Nordisk in licensed commercial facilities at $1,300–$1,500/month. Compounded semaglutide is the same molecule prepared by FDA-registered compounding pharmacies at $99/month. The clinical mechanism, dose schedule, and expected weight-loss outcomes are the same. Quality depends on the pharmacy's standards — Trimi uses accredited pharmacies with third-party batch testing.
Does Medicare cover GLP-1 weight loss medications?
As of 2026, Medicare Part D coverage of GLP-1 medications for weight loss remains limited and varies by plan. Medicare may cover Ozempic for type 2 diabetes or semaglutide for cardiovascular risk reduction under specific Part D plans. The Wegovy weight-loss indication is covered by some Medicare Part D plans following recent policy changes, but coverage is not universal. Contact your specific Part D plan to verify current formulary status.
What if I have Medicaid — can I get a GLP-1?
Medicaid coverage of GLP-1 medications varies significantly by state. Some states have added Wegovy or Ozempic to their Medicaid formularies with specific prior authorization criteria; others do not cover anti-obesity medications at all. Check your state Medicaid program's current preferred drug list (PDL) for the most accurate information.
What should I do if none of the assistance programs work for me?
If manufacturer assistance, insurance coverage, and community health center options are not available to you, compounded semaglutide at $99/month through Trimi is the most accessible direct alternative. No income documentation, no waiting weeks for approval, no prior authorization. A 10-minute online evaluation can get you started within days.
Related Reading
Sources & References
- STEP 1 trial: Wilding JPH et al. Once-Weekly Semaglutide. NEJM 2021;384:989–1002.
- SURMOUNT-1 trial: Jastreboff AM et al. Tirzepatide for Obesity. NEJM 2022;387:205–216.
- HRSA 340B Drug Pricing Program overview.
- KFF. Coverage of GLP-1s for Obesity. 2024.
- FDA guidance on drug compounding.
- CMS memo on Medicare Part D coverage of anti-obesity medications.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication. Program terms, pricing, and eligibility criteria are accurate as of April 2026 and subject to change — verify current details directly with each program.